Qu Jun, Meng Fantao, Wang Zhen, Xu Wenhao
Department of Internal Medicine-Cardiovascular, YanTai YuHuangDing Hospital, Yantai, Shandong, P.R. China.
Department of Internal Medicine-Cardiovascular, LinYi Central Hospital, LinYi, Shandong, P.R. China.
J Microbiol Biotechnol. 2024 Dec 28;34(12):2413-2424. doi: 10.4014/jmb.2405.05019. Epub 2024 Jun 25.
The microbial community inhabiting the human gut resembles a bustling metropolis, wherein beneficial bacteria play pivotal roles in regulating our bodily functions. These microorganisms adeptly break down resilient dietary fibers to fuel our energy, synthesize essential vitamins crucial for our well-being, and maintain the delicate balance of our immune system. Recent research indicates a potential correlation between alterations in the composition and activities of these gut microbes and the development of coronary artery disease (CAD). Consequently, scientists are delving into the intriguing realm of manipulating these gut inhabitants to potentially mitigate disease risks. Various promising strategies have emerged in this endeavor. Studies have evidenced that probiotics can mitigate inflammation and enhance the endothelial health of our blood vessels. Notably, strains such as Lactobacilli and Bifidobacteria have garnered substantial attention in both laboratory settings and clinical trials. Conversely, prebiotics exhibit anti-inflammatory properties and hold potential in managing conditions like hypertension and hypercholesterolemia. Synbiotics, which synergistically combine probiotics and prebiotics, show promise in regulating glucose metabolism and abnormal lipid profiles. However, uncertainties persist regarding postbiotics, while antibiotics are deemed unsuitable due to their potential adverse effects. On the other hand, TMAO blockers, such as 3,3-dimethyl-1-butanol, demonstrate encouraging outcomes in laboratory experiments owing to their anti-inflammatory and tissue-protective properties. Moreover, fecal transplantation, despite yielding mixed results, warrants further exploration and refinement. In this comprehensive review, we delve into the intricate interplay between the gut microbiota and CAD, shedding light on the multifaceted approaches researchers are employing to leverage this understanding for therapeutic advancements.
居住在人体肠道内的微生物群落就像一座熙熙攘攘的大都市,其中有益细菌在调节我们的身体功能方面发挥着关键作用。这些微生物能巧妙地分解坚韧的膳食纤维来为我们提供能量,合成对我们健康至关重要的必需维生素,并维持我们免疫系统的微妙平衡。最近的研究表明,这些肠道微生物的组成和活动变化与冠状动脉疾病(CAD)的发展之间可能存在关联。因此,科学家们正在深入探索操纵这些肠道微生物居民以潜在降低疾病风险的有趣领域。在这一努力中已经出现了各种有前景的策略。研究证明,益生菌可以减轻炎症并改善我们血管的内皮健康。值得注意的是,乳酸杆菌和双歧杆菌等菌株在实验室环境和临床试验中都受到了广泛关注。相反,益生元具有抗炎特性,在管理高血压和高胆固醇血症等病症方面具有潜力。将益生菌和益生元协同结合的合生元在调节葡萄糖代谢和异常血脂方面显示出前景。然而,关于后生元仍存在不确定性,而抗生素由于其潜在的不良影响被认为不适用。另一方面,三甲胺氧化物(TMAO)阻断剂,如3,3 - 二甲基 - 1 - 丁醇,由于其抗炎和组织保护特性,在实验室实验中显示出令人鼓舞的结果。此外,粪便移植尽管结果参差不齐,但值得进一步探索和完善。在这篇全面的综述中,我们深入探讨了肠道微生物群与CAD之间的复杂相互作用,揭示了研究人员为利用这种理解实现治疗进展而采用的多方面方法。